Sofinnova Ventures — 2021 Investments
6 investments dated 2021 · listed companies and verified rows first · show all
Developing innovative biologic therapeutics with transformative clinical potential.
South San Francisco, US
Board seatMaha Katabi· per SEC Form D
Co-investorsAbingworthKleiner Perkins
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)Gail Maderis(Director)Kristine Ball(Executive Officer, Director)Elaine Chien(Executive Officer)Sarah Walter(Executive Officer)Raju Gadiraju(Executive Officer)
Board seatDavid Kabakoff· per SEC Form D
Co-investorsAdjuvant CapitalBrace PharmaCanaan PartnersLumira VenturesMPM BioImpactOUP (Osage University Partners)+3 more
Pleasanton, US
Chih-Ping Liu(Executive Officer, Director, Promoter)
BoardEdgar G Engleman(Director)
Board seatJames Healy· per SEC Form D
Co-investorsVivo Capital
BiotechStevenage, Hertfordshire
Ian Pitfield(Executive Officer)David Fellows(Director)Jessica Stitt(Executive Officer)Renee Gala(Director)Khurem Farooq(Executive Officer)Edward Lang(Executive Officer)
Board seatMaha Katabi· per SEC Form D · $148M raise · filed Apr 2021
Co-investorsForbion
Advancing clinical candidates for cardiovascular, metabolic and kidney diseases.
BiotechCincinnati, US
Marc de Garidel(Executive Officer, Director)
Co-investorsSofinnova Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.